Compare PLRX & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLRX | ATRO |
|---|---|---|
| Founded | 2015 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 3.5B |
| IPO Year | 2020 | 1995 |
| Metric | PLRX | ATRO |
|---|---|---|
| Price | $1.11 | $67.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.67 | ★ $86.00 |
| AVG Volume (30 Days) | 364.4K | ★ 454.9K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.97 | ★ 276.09 |
| EPS | N/A | ★ 1.31 |
| Revenue | N/A | ★ $862,128,000.00 |
| Revenue This Year | N/A | $14.92 |
| Revenue Next Year | N/A | $8.81 |
| P/E Ratio | ★ N/A | $50.86 |
| Revenue Growth | N/A | ★ 8.39 |
| 52 Week Low | $1.02 | $39.14 |
| 52 Week High | $1.95 | $99.89 |
| Indicator | PLRX | ATRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 34.89 |
| Support Level | $1.12 | $63.78 |
| Resistance Level | $1.26 | $79.86 |
| Average True Range (ATR) | 0.04 | 2.84 |
| MACD | -0.00 | -0.90 |
| Stochastic Oscillator | 27.69 | 5.71 |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Astronics Corporation is a provider of technologies to the aerospace, defense, and electronics industries, offering high-performance electrical power generation and distribution systems, motion systems, lighting and safety systems, avionics products, systems certification, aircraft structures, and automated test systems. The company operates through two reportable segments, Aerospace and Test Systems. The Aerospace segment designs and manufactures products for the aerospace and defense industry and generates the majority of revenue, while the Test Systems segment designs, develops, manufactures, and maintains automated test systems for the aerospace and defense, communications, and mass transit industries. The company derives the majority of its revenue from the United States.